Catalyst Pharmaceuticals, Inc.
CPRX
Classement en actions
#4177
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Prix de l'action
$31.49
Dernière synchronisation: 2026-07-21
Capitalisation boursière
$3.85B
Changement (1 jour)
0.00%
Changement (1 an)
49.88%
Pays
US
Échange Catalyst Pharmaceuticals, Inc. (CPRX)
Catégorie
Healthcare
Ratio P/B pour Catalyst Pharmaceuticals, Inc. (CPRX)
Ratio P/B au October 2026 TTM : 3.80
Selon les derniers rapports financiers et le cours de l'action de Catalyst Pharmaceuticals, Inc., le ratio cours/valeur comptable actuel (TTM) est 3.80. À la fin de 2023, le ratio P/B était de 4.61.
Historique du ratio P/B pour Catalyst Pharmaceuticals, Inc. de 2002 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 3.80 | 11.81% |
| 2024 | 3.40 | -26.24% |
| 2023 | 4.61 | -28.03% |
| 2022 | 6.40 | 89.14% |
| 2021 | 3.38 | 65.99% |
| 2020 | 2.04 | -53.73% |
| 2019 | 4.41 | 13.53% |
| 2018 | 3.88 | -6.36% |
| 2017 | 4.14 | 87.18% |
| 2016 | 2.21 | -38.01% |
| 2015 | 3.57 | -33.94% |
| 2014 | 5.41 | 30.46% |
| 2013 | 4.14 | 363.73% |
| 2012 | 0.89 | -88.01% |
| 2011 | 7.45 | 123.57% |
| 2010 | 3.33 | 167.55% |
| 2009 | 1.25 | -43.83% |
| 2008 | 2.22 | -16.22% |
| 2007 | 2.65 | 41.50% |
| 2006 | 1.87 | -97.79% |
| 2005 | 84.78 | -44.01% |
| 2004 | 151.41 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | 320.54 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | 64.44% |
US
|
|
| 13.2547 | 248.67% |
US
|
|
| 4.208 | 10.69% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 62.63% |
NL
|
